Health News Roundup: US FDA finds control lapses at Catalent plant being sold to Novo; US Senate Democrats grill pharma CEOs on drug prices and more
AstraZeneca, which is a client of Catalent for some of its drug manufacturing, is working to boost its in-house capacity to cut reliance on contract drugmakers, Chief Executive Pascal Soriot told reporters after the release of fourth-quarter results. US FDA puts hold on Gilead's blood cancer therapy trials Gilead Sciences said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company's blood cancer drug following increased risk of patient death in some studies.
![Health News Roundup: US FDA finds control lapses at Catalent plant being sold to Novo; US Senate Democrats grill pharma CEOs on drug prices and more](https://devdiscourse.blob.core.windows.net/devnews/23_12_2021_16_11_27_8166358.jpg)
Following is a summary of current health news briefs.
US FDA finds control lapses at Catalent plant being sold to Novo
U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent, including discovery of a "pest" on the manufacturing line, according to an inspection report. Novo Holdings, the parent company of Novo Nordisk, on Monday announced it was buying Catalent in a $16.5 billion deal that included its Bloomington plant, which it plans to sell to Novo Nordisk to help it produce its popular weight-loss drug Wegovy.
Dengue spreads fast in Brazil prompting emergency health measures
Dengue fever has surged in Brazil's hot rainy season, forcing health authorities to take emergency measures and start mass vaccination against the mosquito-borne illness. In the first five weeks of this year 364,855 cases of infection have been reported, the Health Ministry said, four times more than dengue cases in the same period of 2023.
US Senate Democrats grill pharma CEOs on drug prices
U.S. Senate Democrats grilled three top pharmaceutical executives over the high cost of prescription drugs on Thursday but failed to extract any commitments from them to lower prices.
Bristol Myers Squibb CEO Chris Boerner, Merck CEO Robert Davis, and Johnson & Johnson CEO Joaquin Duato appeared before the Senate Committee on Health, Education, Labor, and Pensions (HELP), with Davis and Duato only agreeing to do so last week in response to a subpoena threat.
EU watchdog looking into impact on drug availability from Catalent-Novo deal
The European Union's drugs regulator said on Wednesday it will investigate any risks to the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk, part of its mandate to prevent drug shortages. The European Medicines Agency told Reuters in a statement that its Medicine Shortages Single Point of Contact (SPOC) Working Party will liaise with member states to gather data on the products manufactured at the sites.
Eli Lilly to offer low-cost insulin, donate to clinics in Minnesota settlement
Eli Lilly agreed to provide low-cost insulin to patients and donate free insulin to clinics, to settle a lawsuit by Minnesota that accused the three largest insulin makers of deceptively raising the price of the diabetes treatment. The settlement filed on Wednesday in a New Jersey federal court calls for Lilly to offer patients in Minnesota who pay out-of-pocket the ability to pay no more than $35 a month for its insulin products.
High-dose opioid reversal spray no better than lower dose in field, US study finds
A high-dose version of the opioid reversal spray naloxone, made by Hikma Pharmaceuticals, did not result in an increased survival rate compared with lower-dose versions of the drug when administered in emergency situations by New York law enforcement, according to a U.S. study. The analysis also suggests that those given the higher 8 milligram strength spray were more than twice as likely to experience opioid withdrawal symptoms compared to other sprays such as Narcan that use a 4 mg dose.
Canada's Conservative leader supports ban on puberty blockers for minors
Canada's Conservative opposition leader Pierre Poilievre on Wednesday expressed support for a gender identity policy that would forbid minors in the Western province of Alberta from receiving hormonal treatments like puberty blockers. Alberta's guidelines, which were announced last week and are expected to be implemented later this year, would be the strictest in Canada. They would ban hormonal treatments for children who are 15 and under, and require parental consent for 16- and 17-year-olds.
Walgreens CEO appoints finance chief, new healthcare unit head
Walgreens Boots Alliance's CEO Tim Wentworth on Thursday finalized the appointment of its finance chief and named a new head of its nascent healthcare unit, as he aims to turn around a dive in the company's stock price. The pharmacy chain operator's stock has declined 38% in the last twelve months as Walgreens grapples with waning demand for COVID products and decreased spending on personal care and beauty products by inflation-weary consumers.
Astrazeneca says Catalent deal shows need for in-house capacity
The sale of listed contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance for big pharma companies of building an independent supply chain, Astrazeneca said Thursday. AstraZeneca, which is a client of Catalent for some of its drug manufacturing, is working to boost its in-house capacity to cut reliance on contract drugmakers, Chief Executive Pascal Soriot told reporters after the release of fourth-quarter results.
US FDA puts hold on Gilead's blood cancer therapy trials
Gilead Sciences said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company's blood cancer drug following increased risk of patient death in some studies. The company will stop testing the drug, magrolimab, for all blood cancers and will review its safety across other studies such as those in patients with colon and breast cancers.
(With inputs from agencies.)
ALSO READ
Pankaj Tripathi to Showcase India’s Rich Heritage at New York India Day Parade
Bollywood Stars, Indian Dignitaries Shine at New York City's India Day Parade
New York Man Charged as Illegal Chinese Agent in U.S.
New York Man Charged as Illegal Chinese Agent in US
UPDATE 2-Senior US officials meet with Dalai Lama in New York